IRCT20210710051831N1 IRCT 2021-08-09 Qazvin University of Medical Sciences The effect of Bosentan in the treatment of pulmonary hypertension in patients with COVID-19 Comparison assessment of Bosentan and routine medication on pulmonary hypertension among hospitalized patients with COVID-19 2021-08-23 anticipated 60 Complete https://irct.ir/trial/57474 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random sampling is simple in that the names of all patients participating in the project is written and 60 people, which is equivalent to the sample size, will be selected by lot and through Permuted- Block randomization with blocks of size 8 (consisting of 4 participants in the intervention and 4 participants in the control groups) is used for random allocation, Blinding description: Blinding in this study is double blind that the drug and placebo are labeled by the manufacturer as "Group A" and "Group B". They are quite similar in appearance and the person participating in the study and the person distributing the medicine does not know about this labeling. the drug and placebo were labeled by the manufacturer Group A and Group B. Which are quite similar in appearance and the person participating in the study and the person distributing the medicine does not know about this labeling. 2-3 Condition 1: COVID-19. Condition 2: COVID-19. Intervention 1: Intervention group: The case group in addition to the drugs used in the treatment of COVID-19 (approved by the National Committee), is treated with Bosentan 62.5mg twice a day for 10 days. Intervention 2: Control group: Patients receive only the drugs used to treat COVID-19 (approved by the National Committee). No - There is not a plan to make this available Justification or reason for not sharing IPD is Confidentiality of patient information